#1
#1 out of 1
business1d ago
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade
- Tarsus Pharmaceuticals confirms a significant RSU-related sale by its Chief HR Officer in mid-March 2026, totaling about $839,000.
- The sale used a mandatory sell-to-cover structure tied to RSU vesting, signaling tax mechanics rather than a strategic stock bet.
- Post-trade, Whitfield’s direct holdings stood at 35,028 shares, valued around $2.34 million at the time.
- The sale represented about 25.95% of Whitfield’s direct holdings, reducing exposure in the near term.
- No indirect entities or derivatives were involved in the sale, per the Form 4 filing.
- The weighted average sale price was about $68.36 per share, with the market close near $66.75 on trade day.
- Tarsus Pharmaceuticals highlighted strong 2025 sales and cash runway amid ongoing pipeline catalysts.
- The FT Motley Fool piece notes management intends to advance TP-03 and other pipeline assets with Phase 2 catalysts.
- Analysts caution the insider sale may not reflect broader company sentiment toward fundamentals.
- The stock's performance context shows a 22.48% total return over the past year as of the transaction date.
Vote 0